Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Mothaffar Rimawi

Professor, Executive Medical Director

Baylor College of Medicine

United States

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

70%

Medical Imaging

20%

Oncology

40%

Cancer Biology

40%

Targeted Therapy

30%

Neoadjuvant Therapy

30%

Cancer Therapy

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Close

A New Paradigm for De-Escalation of Treatment in HER2-Positive Breast Cancer: Revolutionizing Care with More Effective and Less Toxic Therapy

Open Date: 2015-10-01

Close Date: 2016-09-01

Grant: Close

NSABP Participating Sites

Open Date: 2006-04-10

Close Date: 2013-01-31

Articles10

Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies

Article Link

Year:

2024

Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins

Article Link

Year:

2023

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis

Article Link

Year:

2023

Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2–Expressing Metastatic Breast Cancer

Article Link

Year:

2023

Margetuximab in HER2-positive metastatic breast cancer

Article Link

Year:

2023

Elacestrant and the Promise of Oral SERDs

Article Link

Year:

2022

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis

Article Link

Year:

2021

Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer

Article Link

Year:

2021

Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases

Article Link

Year:

2020

Towards personalized treatment for early stage HER2-positive breast cancer

Article Link

Year:

2020

Collaborators11

Rachel Schiff

Professor

Baylor College of Medicine

UNITED STATES

Meenakshi Anurag

Assistant Professor (Tenure track)

Baylor College of Medicine

UNITED STATES

Foluso O. Ademuyiwa

UNITED STATES

Saundra S. Buys

UNITED STATES

Ruth M. O’Regan

UNITED STATES

Guy Jerusalem

BELGIUM

Anna Malovannaya

Baylor College of Medicine

UNITED STATES

Juan Rafael de la Haba Rodríguez

Profesor Titular

Universidad de Córdoba

SPAIN

Valentina Hoyos

Baylor College of Medicine

UNITED STATES

PIERFRANCO CONTE

Professore di 1^ fascia

University of Padova

ITALY

Jamunarani Veeraraghavan

Assistant Professor

Baylor College of Medicine

UNITED STATES

How do I reach out?

Meet Kite AI